Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharma (NQ: RETA )

93.80 -0.30 (-0.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 619,165
Open 93.96
Bid (Size) 90.50 (4)
Ask (Size) 95.19 (2)
Prev. Close 94.10
Today's Range 92.86 - 94.86
52wk Range 18.47 - 106.69
Shares Outstanding 36,948,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bragar Eagel & Squire, P.C. Is Investigating Reata, Comerica, and DZS and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga

Performance

YTD
+155.52%
+155.52%
1 Month
+3.78%
+3.78%
3 Month
+13.07%
+13.07%
6 Month
+163.34%
+163.34%
1 Year
+171.02%
+171.02%

More News

Read More
NASDAQ:RETA Investor Alert: Investigation over Possible Securities Laws Violations by Reata Pharmaceuticals, Inc.
Via SBWire
Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals Stock Plummets More Than 20%: Here's Why
Via Benzinga
Reata Pharma Tumbles After Scrapping Its Kidney Drug As Earnings Come In Mixed
Via Investor's Business Daily
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Via Investor's Business Daily
Recap: Reata Pharmaceuticals Q1 Earnings
Via Benzinga
Earnings Outlook For Reata Pharmaceuticals
Via Benzinga
Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 5/5
Via Investor Brand Network
Where Reata Pharmaceuticals Stands With Analysts
Via Benzinga
REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Abercrombie & Fitch, Urban Outfitters, Photronics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023
From Reata Pharmaceuticals, Inc.
Via Business Wire
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
Via The Motley Fool
REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA
From Kahn Swick & Foti, LLC
Via Business Wire
The 3 Best Growth Stocks to Buy in the Biotech Sector
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.